MedMira Completes Registration in United Arab Emirates Health Ministry Approves Rapid HIV and HCV Tests for Sales to Government Facilities HALIFAX, April 28 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow-through diagnostic technology, announced today that it has successfully completed the registration process with the Ministry of Health in the United Arab Emirates (UAE). This registration enables MedMira to participate in government tenders and sell its rapid HIV and Hepatitis C tests to government healthcare facilities, where 70% of all HIV and Hepatitis C testing is conducted in the UAE. MedMira and its distributor, Prestige Group (part of the US$4.5 billion Al Jaber Group of Establishments), have established a solid position in the Middle East's private healthcare sector with sales of the MiraWell(TM) Rapid HIV Test and MiraWell(TM) Rapid HCV Test. MedMira's rapid tests are the fastest flow-through diagnostic tests in the world, providing results in 3 minutes. Rapid diagnostic tests present significant value in the UAE market, where expatriates make up 80% of the population and must be tested for HIV every two years as part of the visa renewal process. Giles Crouch, Vice President of Marketing and Business Development with MedMira said, "We worked closely with Prestige Group to quickly advance through the registration process and qualify MedMira's products for government tenders. This strong working relationship and our distributor's continued commitment to the MedMira product portfolio will further increase our presence and leadership position in this important market." Crouch added, "We expect to expand this market in the near future by introducing the first over-the-counter (OTC) rapid HIV test to the Middle East market." The World Health Organization (WHO) estimates that approximately 83,000 people were newly infected with HIV in the Middle East region in 2003 and that about 0.3 percent of adults in the region are currently infected. With an estimated 200 million people worldwide infected with hepatitis C, and some 40% of those with HIV being co-infected with hepatitis C, the combination of MiraWell(TM) Rapid HIV Test and MiraWell(TM) Rapid HCV Test will play a critical role in the Middle East healthcare system. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow-through rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counselling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter (OTC) in pharmacies throughout the Hong Kong and Macao Special Administrative Regions, in the People's Republic of China. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira's website at http://www.medmira.com/. DATASOURCE: MedMira Inc. CONTACT: Dr. James Smith, Investor Relations, Tel: (902) 450-1588, E-mail:

Copyright